ABAD-SANTOS, F. et al. Efficacy of inhaled zanamivir for the treatment and prevention of influenza. []. , 18, 2, pp.49-55. ISSN 0212-7199.

The aim of this work is to evaluate the efficacy of zanamivir in the treatment and prevention of influenza. This drug is a neuraminidase inhibitor that is effective against both A and B influenza viruses. Five randomized, double-blind, placebo-controlled, clinical trials have been published, showing a reduction in the duration of flu symptoms between 1 and 2.5 days. A greater benefit is seen in the patients with influenza-confirmed infection, with fever and when the treatment begins in the first 30-36 hours. For the prevention of influenza, two placebo-controlled clinical trials have been published, where flu incidence wass reduced by 50-67%. The characteristics of zanamivir (efficacy, safety and lack of resistance) make it an appropriate option for subjects not protected by vaccination and for those with high risk of complications.

: Zanamivir; Neuraminidase inhibitors; Antiviral agents; Influenza; Review.

        · |     · |     · ( pdf )